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ponsibility of InstituAbstract This study assessed the inﬂuence of the composition of drug-free SNEDDS co-dosed with
aqueous suspensions of carvedilol (CAR), cinnarizine (CIN) or R3040 on drug solubilization in a two-
compartment in vitro lipolysis model. Correlation of drug logP or solubility in SNEDDS with drug
solubilization during in vitro lipolysis in the presence of drug-free SNEDDS was assessed. SNEDDS with
varying ratios of soybean oil:Maisine 35-1 (1:1, w/w) and Kolliphor RH40, with ethanol at 10% (w/w) were
used. SNEDDS were named F65, F55 and F20 (numbers refer to the percentage of lipids) and aqueous
suspensions without drug-free SNEDDS (F0) were also analyzed. While the ranking order of drug
solubilization was F65¼F55¼F204F0 for CAR; F65¼F554F204F0 for CIN and F65¼F55¼F204F0
for R3040 - with higher CAR solubilization than for R3040 and CIN - the ranking of Seq of CAR, CIN and
R3040 in SNEDDS was F65oF55oF20, F65¼F554F20 and F654F554F20, respectively. Therefore, the
composition of SNEDDS inﬂuenced the solubilization of CIN, but not CAR and R3040. Furthermore, high Seq
in SNEDDS did not reﬂect high drug solubilization. As CAR (logP 3.8) showed higher solubilization than
CIN (logP 5.8) and R3040 (logP 10.4), a correlation between drug logP and drug solubilization was observed.
& 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).l Association and Institute of Materia
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Table 1 Composition of the drug-free SNEDDS.
Formulationsa Excipient (%, w/w)
Soybean oil:
Maisineb
Kolliphor
RH40
Ethanol
F65 65 25 10
F55 55 35 10
F20 20 70 10
aF65, F55 and F20 mean SNEDDS containing 65%, 55% and
20% of lipid mixture.
bsoybean oil:Maisine¼1:1, w/w, respectively.
Exploring the utility of the Chasing Principle 1951. Introduction
Oral administration remains the preferred route for drug adminis-
tration due to ease of administration, easy patient compliance and
established manufacturing processes1. However, the increasing
number of poorly water-soluble compounds developed by the
pharmaceutical industry, leading to limited oral drug absorption,
calls for advanced drug delivery systems2. Self-nanoemulsifying
drug delivery systems (SNEDDS) have shown to improve the oral
bioavailability of many poorly water-soluble drugs2–8. Usually,
SNEDDS contain the drug dissolved in a lipid based water-free
preconcentrate, thereby avoiding the dissolution step of the solid
drug prior to absorption, which is believed to be one of the
advantages of SNEDDS9–11. However, there are two main
problems concerning the application of SNEDDS for broader
use; ﬁrstly, many drugs show low solubility in pharmaceutically
relevant lipids, which can result in low drug loads in SNEDDS and
secondly, a number of drugs have low chemical stability in the
presence of lipids12. Application of SNEDDS with a low drug load
result in the need to dose a higher dose of excipients, which can be
a point of concern especially when high drug doses are needed,
e.g., in toxicological studies. However, it has been demonstrated
that having the drug dissolved in SNEDDS is not a strict condition
for improved drug absorption9. In fact, the successful use of lipid
suspensions to improve the bioavailability of griseofulvin, pheny-
toin, cinnarizine (CIN), danazol and fenoﬁbrate has previously
been described9,13–15. One of the reasons for this is likely to be
related to the presence of lipids and their digestion products in the
gastrointestinal tract, upon administration of the drug lipid
suspension. These digestion products, e.g., monoacylglycerides
and free fatty acids, play an important role in solubilization and
absorption of poorly water-soluble compounds16,17. In support of
this, it has been demonstrated that a number of poorly water-
soluble drugs, dosed in tablets, show a positive food effect, i.e.,
drug absorption is enhanced when ingested with a (high fat)
meal12. This is partly due to the postprandial increase in the
concentrations of bile salts, phospholipids and the products of lipid
digestion in the intestine, which facilitates the dissolution and
solubilization of some drugs because of the presence of mixed
micelles and uni- and multi-lamellar vesicles16,18–21. In this
context, Christiansen et al.12 have shown that under fasted state
conditions, the co-administration of 0.5 g of drug-free SNEDDS
(sesame oil, Cremophor RH40, oleic acid, Brij and ethanol) with a
CIN tablet (Sepans) induced an increased extent of CIN absorp-
tion in humans compared to the administration of a CIN tablet
without drug-free SNEDDS.
Recently, the co-administration of a drug-free SNEDDS and
a CIN aqueous suspension (so called Chasing Principle)
displayed a comparable absorption proﬁle in rats to that of
CIN dosed in a SNEDDS solution5. This has been explained by
an enhanced solubilization of the drug in the presence of lipids,
the lipid digestion products and the formed colloidal struc-
tures4,5. Similarly, Larsen et al.22 found no signiﬁcant differ-
ences in the absorption of CIN, danazol or halofantrine when
the drugs were dosed either as the Chasing Principle (co-dosed
with drug-free Labraﬁl M2125CS) or pre-dissolved in Labraﬁl
M2125CS. The main advantages of the Chasing Principle are
the ease of preparation, the fact that the drug dose is not limited
by the drug solubility in the SNEDDS preconcentrate, and its
suitability for drugs that are chemically unstable in the presence
of lipids5.Considering the advantages of the Chasing Principle as an
approach to improve the in vivo exposure of poorly water-soluble
compounds, the primary aim of this work was to assess if the
composition of (drug-free) SNEDDS would inﬂuence the solubi-
lization of carvedilol (CAR), CIN or R3040 in an in vitro lipolysis
model simulating rat gastrointestinal conditions. The in vitro
lipolysis model contained a gastric and intestinal compartment,
where drug dispersion was assessed in the gastric compartment
and digestion and drug solubilization were assessed in the
intestinal compartment. A second aim was to investigate if a high
drug solubility (Seq) in the SNEDDS would reﬂect high drug
dispersion and solubilization in the in vitro lipolysis model, upon
co-dosing of an aqueous suspension of a drug with drug-free
SNEDDS. Furthermore, the correlation between the logP of the
drug and the ability of the drug to be dispersed and solubilized in
the presence of SNEDDS was assessed. The model drugs were
selected based on their different physicochemical properties to
represent a range of poorly water-soluble compounds. CAR is a
β-adrenergic antagonist used in cardiovascular diseases23, CIN is a
calcium antagonist used in the treatment of motion sickness12 and
R3040 is a research compound from F. Hoffmann - La Roche,
Switzerland. Three SNEDDS with increasing lipophilicity were
used (Table 1). The distribution of CAR, CIN and R3040 in the
aqueous phase was determined during gastric dispersion and
intestinal digestion using a two-compartment in vitro lipolysis
model simulating rat gastrointestinal conditions.2. Materials and methods
2.1. Materials
CIN (C-5270), soybean oil (long-chain glycerides), bile extract
(bovine) (B-3883), and porcine pancreatic lipase extract (P-1625)
were purchased from Sigma–Aldrich (Saint Louis, MO, USA).
R3040 was donated by F. Hoffmann-La Roche (Basel, Switzer-
land). CAR was donated by Cipla Ltd. (Pune, India). Maisine 35-1
(a mixture of long chain mono-, di-, and triglycerides) was donated
by Gattefossé (St. Priest, France), Kolliphor RH 40 was donated
by BASF (Ludwigshafen, Germany), and soy phospholipid (S-PC)
was purchased from Lipoid (Ludwigshafen, Germany). Sodium
hydroxide and calcium chloride dihydrate were purchased from
Merck (Darmstadt, Germany). Sodium chloride and 4-
bromobenzeneboronic acid (4-BBBA) was obtained from Fluka
Chemie AG (Buchs, Switzerland). Ethanol (Ph. Eur. grade) and
acetonitrile (HPLC grade) were purchased from VWR (Herlev,
Denmark).
Figure 1 Schematic representation of the rat in vitro lipolysis model.
Gastric (1) and intestinal compartments (2) are connected by a
peristaltic pump. Initially, 7.9 mL of the gastric content were trans-
ferred manually followed by the ﬂows described above.
Table 2 Composition of the lipolysis media before initiation
of the gastric transfer.
Component Initial concentration
Gastric
compartment
Intestinal
compartment
Bile salts (mmol/L) 0.08 50
Phospholipids (mmol/L) 0.02 3.7
Sodium chloride
(mmol/L)
34.2 70
Maleic acid (mmol/L) 2 2
Tris (mmol/L) – 2
Enzyme activity
(USP/mL)
– 17926
Gastric volume (mL) 20 –
Initial intestinal
volume (mL)
– 65þ5 (pancreatin
solution)
pH 4 6.5
Scheyla Daniela Siqueira Jørgensen et al.1962.2. Preparation of formulations
The composition of the three SNEDDS used in this study is shown
in Table 1. SNEDDS were prepared as previously described24.
Brieﬂy, Maisine 35-1 (heated to 50 1C) was mixed with soybean
oil followed by the addition of Kolliphor RH 40 (heated to 50 1C)
and ethanol.
Aqueous suspensions (F0) of CAR, CIN and R3040 at 25mg/mL,
suspended in 0.5% (w/v) methylcellulose solution containing 5%
propylene glycol were prepared. The droplet sizes of F65, F55 and
F20 have been previously determined by Thomas et al.24. The particle
size of the aqueous suspensions was determined using a Mastersizer S
from Malvern Instruments Ltd. (Worcester, UK). Immediately before
the measurements, the suspensions were dispersed in puriﬁed water at
a dilution of 1:50 (v/v).2.3. Two-compartment in vitro lipolysis model
An in vitro lipolysis model simulating rat gastrointestinal condi-
tions was used as previously described. The rat gastrointestinal
conditions were simulated in terms of volume of gastrointestinal
ﬂuids, pH, enzyme activity and bile salt and phospholipid
concentrations, based on a literature review. Brieﬂy, the model
was composed of two compartments representing the rat stomach
and intestine, which were connected by a peristaltic pump (Fig. 1,
Ismatec, NJ, USA).
Even though bile salts and phospholipids are secreted into the
duodenum together with bile, there is reﬂux from the duodenal
ﬂuids into the stomach of the rat, as described by Tanaka et al.25.
Therefore, low concentrations of bile salts and phospholipids were
added in the gastric medium used in the current in vitro lipolysis
model. The compositions of the gastric and the initial intestinal
media, the enzyme activity in the intestinal compartment, the
volumes of media used in each compartment and the respective pH
values are shown in Table 2.
In the gastric compartment, drug solubilizationi in the presence
of the drug-free SNEDDS was assessed in order to investigate how
much drug was solubilized prior to the transfer to the intestinal
compartment. Brieﬂy, 1.5 mL of drug-free SNEDDS and 6 mL of
aqueous suspensions of CAR, CIN or R3040, at 25 mg/mL were
added into 20 mL of gastric medium at 37 1C (composition iniThe solubilization assessed in the gastric compartment was determined
in an independent experiment, where the gastric compartment was not
connected to the intestinal compartment.Table 2) and stirred for 30 min. Samples were collected after 30
min of stirring and centrifuged at 19,000 g for 15 min. The drug
concentration in the supernatant was determined by HPLC as
described below.
In vitro digestion in the intestinal compartment was initiated after
3 min of dispersion of the formulations in the gastric compartment;
then, 7.9 mL of the gastric content were manually transferred to the
intestinal compartment followed by the pump ﬂows described in
Fig. 1. At the same time of the initiation of the gastric transfer, 5 mL
of pancreatic enzyme solution were added into 65mL of intestinal
medium in the intestinal compartment (Compartment 2 in Fig. 1)
generating a lipase activity of 179 units/mL in the intestinal medium
(Table 226) where one unit corresponds to 1 mmol of fatty acid
released per minute27,28. The pancreatic enzyme solution was
prepared by weighing the pancreatic extract in a polypropylene
tube followed by the addition of puriﬁed water2. The blend was
vortexed until homogeneous and subsequently centrifuged at
6500 g for 7 min. The supernatant was isolated and used as the
pancreatic enzyme solution. The pH in the intestinal compartment
was maintained at 6.5 by adding 0.4mol/L NaOH to correct for the
pH changes caused by lipid digestion and the constant addition
of the gastric content at pH 4. A continuous addition of calcium
(0.5mol/L CaCl2) at a rate of 0.01 mL/min was used to control the
lipolysis rate29. In the intestinal compartment, the lipolysis was run
for 60min at 37 1C and 1.05 mL samples were collected at 5, 15, 30
and 60min. The collected volumes were replaced by fresh drug-free
intestinal medium and the enzyme activity in the collected samples
was inhibited by the addition of 7 mL of 4-BBBA (1mol/L in
methanol). Subsequently, the samples were centrifuged at
19,000 g for 15min and the drug content in the supernatant
was determined by HPLC as described below. To correct for the
lipolysis of the plain medium and the pH shift from the transfer of
the gastric content to the intestinal compartment, a lipolysis without
lipid formulation was performed.2.4. Solubility of CAR, CIN and R3040 in SNEDDS and gastric
and intestinal lipolysis media
The saturation solubility (Seq) of the drugs was determined by
adding an excess of CAR, CIN or R3040 to the SNEDDS
Table 3 Physicochemical properties of the model drugs.
Physicochemical property CAR CIN R3040
Solubility in F65 (mg/g) 2571 2671 216713
Solubility in F55 (mg/g) 4273 25715 20577
Solubility in F20 (mg/g) 7375 2070 7474
Solubility in gastric medium
(mg/mL)
333718 5771 872
Solubility in initial
intestinal medium
(mg/mL)
669729 8473 3474
Aqueous solubility (mg/mL) 3730 2031 o132
pKa 7.9
30 1.9 and Neutral32
Exploring the utility of the Chasing Principle 197(Table 1) or lipolysis media (gastric and intestinal media, Table 2).
The suspensions were kept in a rotator (HETO, Birkerød, Den-
mark) at 25 1C for SNEDDS, and at 37 1C for the lipolysis media.
To determine the Seq in SNEDDS, at each 24 h interval, a clear
supernatant was obtained by centrifugation at 19,000 g for
15 min. To determine the Seq in the lipolysis media without
SNEDDS, the drug concentration in the supernatant was analyzed
after 24 h. After centrifugation, the supernatants were appropri-
ately diluted with acetonitrile and the drug content was determined
by HPLC as described below. The drug solubility in SNEDDS was
considered to be the Seq when the values of drug concentration in
the supernatants varied less than 5%. The solubility determinations
were performed in triplicate.7.4731
LogP 3.830 5.831 10.4
Particle size (diameter, mm)a 2370 5071 1070
aParticle size of aqueous suspensions of CAR, CIN and R3040.
Data are presented as mean7SD (n¼3).2.5. HPLC analysis
The drug concentrations in the samples from the solubility studies
and in vitro lipolysis were determined using a HPLC system
composed of a Dionex ASI 100 automated sample injector, a P680
HPLC pump and a PDA-100 photo diode array detector (Thermo
Fisher Scientiﬁc, Waltham, MA, USA). For each compound, a
Phenomenex C18 (4.60 mm 150 mm, 5 mm) column (Torrance,
CA, USA) was used. CAR was analyzed at a wavelength of 240
nm with a mobile phase consisting of acetonitrile:10 mmol/L
potassium phosphate buffer at pH 2 (52:48, v/v). CIN was
analyzed at a wavelength of 253 nm with a mobile phase
consisting of acetonitrile: 20 mmol/L ammonium dihydrogen
phosphate monobasic buffer at pH 4.5 (50:50, v/v) and R3040
was analyzed at a wavelength of 225 nm with a mobile phase
consisting of acetonitrile and water (90:10, v/v). All model drugs
and mobile phases were eluted at a ﬂow rate of 1 mL/min and an
injection volume of 10 mL.2.6. Statistical analysis
The data sets are expressed as mean 7 standard deviation of the
mean (SD) and one-way ANOVA followed by Tukey's test was
used to analyze statistical differences between groups. The
statistical analyses were performed using GraphPad Prism 7
(GraphPad Software, San Diego, CA, USA).3. Results and discussion
The current study assessed if the composition of drug-free
SNEDDS co-dosed with aqueous suspensions of CAR, CIN or
R3040 (Chasing Principle) would affect the solubilization of the
model drugs using an in vitro lipolysis model simulating rat
gastrointestinal conditions. In addition, it was investigated if there
is a correlation between the solubilization proﬁles of a drug during
in vitro lipolysis, the Seq of the drug in SNEDDS and the logP of
the drug. The three drug-free SNEDDS where designed by
changing the ratio between lipid and surfactant, keeping the
ethanol concentration constant (Table 1).3.1. Physicochemical properties of the model drugs
Table 330–32 summarizes the physicochemical properties of CAR,
CIN and R3040. Probably due to its comparatively low logP (3.8),
the Seq of CAR increased from 2571 to 7375 mg/g when thelipid content of the drug-free SNEDDS was decreased from 65%
(F65) to 20% (F20) (Table 3).
In contrast, CIN (logP 5.8) had a higher saturation solubility in
F65 (2671 mg/g) and F55 (2571 mg/g) than in F20 (2070 mg/g)
(Po0.05), possibly due to the low glycerides content of F20
(Table 3). The low Seq of CIN in F20 is supported by the ﬁndings
of Larsen et al.33 who showed that CIN had higher Seq in
SNEDDS containing higher concentrations of glycerides than in
SNEDDS containing higher concentrations of the surfactant
Kolliphor RH40. For R3040, which has a high clogP (10.4),
higher Seq values were found in F65 (216713 mg/g) and F55
(20577 mg/g) than in F20 (7474 mg/g) (Po0.05) (Table 3).
All model drugs had a higher solubility in the intestinal medium
than in the gastric medium. Although CAR and CIN are weak
bases (Table 3), the high bile salt level in the initial intestinal
medium (50 mmol/L) resulted in a signiﬁcantly higher drug
solubility in this medium (Table 3).
3.2. Solubilization of CAR, CIN and R3040 in the gastric
compartment in the presence of drug-free SNEDDS
After 30 min of dispersion of drug-free SNEDDS co-dosed with
the drug aqueous suspensions (Chasing Principle) in the gastric
compartment, the concentration of drug in the aqueous phase
was determined to assess drug solubilization in the gastric
compartment. The differences between the gastric and the
intestinal compartments are that in the gastric compartment
there is no enzyme activity and the pH, bile salts and
phospholipids levels are lower than in the intestinal medium
(Table 2). In addition, as the drug-free SNEDDS and aqueous
suspensions are dosed into the gastric compartment and subse-
quently slowly transferred to the intestinal compartment
(Fig. 1), the concentrations of lipid and drug in the gastric
compartment are higher than in the intestinal compartment.
Fig. 2 shows that none of the model drugs were completely
solubilized before the transfer to the intestinal compartment. F65
and F55 could not solubilize CAR in the gastric compartment to
the same extent as F20 (Po0.05), possibly due to the lower Seq of
CAR in F65 and F55 compared to F20 (Table 3). For CIN,
however, the formulation containing the lowest concentration of
lipids (F20) showed the lowest ability to solubilize CIN (Po0.05),
Scheyla Daniela Siqueira Jørgensen et al.198which correlates with the low CIN Seq in F20 (Table 3). Therefore,
an increase in the concentration of lipids from 20% in F20 to 55%
and 65% in F55 and F65, had a signiﬁcant inﬂuence on CIN
solubilization (Po0.05). R3040 showed the lowest solubilization
when co-dosed with F65, F55 or F20, in comparison to the
solubilization of CAR and CIN (Fig. 2). This may be related to the
high logP of R3040 (10.4) and its low solubility in the gastric
medium (Table 3).
In Fig. 2, it is observed that CAR showed higher solubilization
than CIN and R3040. Considering that CAR has the lowest logP,
compared to the logP of CIN and R3040 (Table 3), there seems to
be a relation between drug logP and drug solubilization in the
gastric compartment.3.3. Solubilization of CAR, CIN and R3040 in the intestinal
compartment
The concentration of fatty acids formed during in vitro lipolysis of
the drug-free SNEDDS, corrected for the lipolysis of the plain
intestinal medium and the pH shift from the gastric compartment, is
shown in Fig. 3. Lipolysis of the plain medium is mainly a result of
the enzymatic conversion of phospholipids to lysophospholipids and
to some degree impurities in the pancreatin and the crude bile
extract34. As can be seen in Fig. 3, the higher concentrations of lipids
in F65 and F55 led to a higher formation of free fatty acids compared
to F20, which contained the lowest concentration of lipids.Figure 3 Free fatty acids generated in the intestinal compartment
during in vitro lipolysis (mean7SD, n¼3). F65 ( ), F55 ( ) and
F20 ( ).
Figure 2 Distribution of CAR, CIN and R3040 in the aqueous phase
after 30min of dispersion in the gastric compartment (mean7SD, n¼3).
CAR, CIN and R3040 aqueous suspensions were co-dosed with F65, F55
and F20.In vitro lipolysis of plain aqueous suspensions (F0) of CAR,
CIN and R3040 was carried out to exclude the possibility that a
high bile salt concentration in the intestinal step (Table 2) would
have similar solubilization capacity as F65, F55 and F20 and
therefore hamper the interpretation of the data. Furthermore, the
advantage of dosing drug aqueous suspensions with drug-free
SNEDDS was assessed by comparing the solubilization of CAR,
CIN and R3040 dosed as aqueous suspensions without drug-free
SNEDDS.
As CAR, CIN and R3040 dosed as aqueous suspensions
without the drug-free SNEDDS showed lower drug concentra-
tions in solution than the drugs co-dosed with drug-free
SNEDDS (Figs. 4, 5 and 6), the high bile salt concentration
in the intestinal step did not solubilize the model drugs to the
same extent as the drug-free SNEDDS. Furthermore, the
solubilization potential of the drug-free SNEDDS on the
CAR, CIN and R3040 solubilization has been demonstrated.
The key factors inﬂuencing the solubilization ability of
SNEDDS during in vitro digestion are associated with the
digestibility of the excipients and the resulting digestion
products formed35. In addition, the kinetics of drug partitioning
between the colloidal structures and SNEDDS droplets, also
play a role in the solubilization of poorly water-soluble drugs
dosed in SNEDDS during lipolysis36.Figure 4 Distribution of CAR in the aqueous phase of the intestinal
compartment during in vitro lipolysis (mean7SD, n¼3). F65 ( ),
F55 ( ), F20 ( ), F0 ( ) and total drug concentration (-♦-). The
SD values were smaller than the symbols.
Figure 5 Distribution of CIN in the aqueous phase of the intestinal
compartment during in vitro lipolysis (mean7SD, n¼3). F65 ( ), F55
( ), F20 ( ), F0 ( ) and total drug concentration (-♦-).
Figure 6 Distribution of R3040 in the aqueous phase of the intestinal
compartment during in vitro lipolysis (mean7SD, n¼3). F65 ( ), F55
( ), F20 ( ), F0 ( ) and total drug concentration (-♦-).
Exploring the utility of the Chasing Principle 199Due to the gradual transfer of the gastric content to the intestinal
compartment during in vitro lipolysis, the total ﬁnal drug
concentrations (black diamonds in Figs. 4–6) increased from
approximately 700 mg/mL, at the beginning of in vitro lipolysis,
to 1300 mg/mL at 60 min of in vitro lipolysis. Fig. 4 shows that
while less than 100 mg/mL of CAR were solubilized when dosed in
aqueous suspension without drug-free SNEDDS, F65, F55 and
F20 were able to keep more than 500 mg/mL of CAR in solution
during the course of the in vitro lipolysis. Therefore, the co-dosing
of drug-free SNEDDS played an important role in the solubiliza-
tion of CAR. In addition, the lower solubility of CAR in F65 and
F55 compared to the CAR solubility in F20 (Table 3) was not
reﬂected in lower solubilization capacity of F65 and F55 for CAR
during the in vitro lipolysis (Fig. 4). This may be due to the low
logP of CAR and the subsequently high solubility in the intestinal
medium (Table 3).
When CIN was co-dosed with F65 and F55, increasing and
superimposable proﬁles of drug solubilization were obtained
(Fig. 5). However, when CIN was co-dosed with F20, the
concentration of CIN in solution was lower than when co-dosed
with F65 and F55, but still signiﬁcantly higher than for the
aqueous suspension without drug-free SNEDDS (Po0.05)
(Fig. 5). The low ability of F20 to solubilize CIN correlates with
the lower CIN Seq in F20 compared to the CIN Seq in F65 and F55
(Table 3). Therefore, the concentrations of mono-, di- and
triglycerides in the drug-free SNEDDS and the generation of free
fatty acids upon lipid digestion were important for the solubiliza-
tion of CIN. Previous studies have shown that free fatty acids
have a profound impact on CIN solubilization16,37,38; e.g.,
Larsen et al.37 showed that the solubility of CIN in lipolysis
medium increased as a function of increasing levels of fatty acids.
The Seq of R3040 in F65 and F55 (Table 3) would suggest that
the capacity of F65 and F55 to solubilize R3040 in the in vitro
lipolysis model would be higher than the capacity of F20.
However, independent of which formulation was co-dosed with
R3040 aqueous suspension, no signiﬁcant improvement on the
R3040 solubilization was obtained (Fig. 6).
The droplet sizes of F65, F55 and F20 are 11072, 4471 and
2672 nm, respectively. Thus, decreasing the concentrations of
the lipid mixture soybean oil:Maisine and increasing Kolliphor
RH40 concentrations in F65, F55 and F20 (Table 1) resulted in
decreased SNEDDS droplet sizes. Correspondingly, Tran et al.39
have shown that increasing the concentration of Kolliphor RH40
from 30% to 50% (w/w) in SNEDDS containing soybean oil:Maisine as lipid mixture, signiﬁcantly decreased SNEDDS
droplet size. Considering the differences in droplet size of
F65, F55 and F20, and the similar solubilization abilities
towards CAR, CIN and R3040 (Figs. 2–6), it is observed that
SNEDDS droplet size did not affect the solubilization ability of
SNEDDS during in vitro lipolysis.
Comparing the solubilization of CIN and R3040, it is observed
that the solubilization of CIN was signiﬁcantly higher than the
solubilization of R3040 (Figs. 5 and 6). This ﬁnding would suggest
that in vivo, the Chasing Principle would provide higher absorption
of CIN than for R3040. This hypothesis is supported by two
previous pharmacokinetic studies in rats where R304026 or CIN5
were dosed in SNEDDS (same composition as F55) using different
drug loads and physical states of the drug, i.e., dissolved in
SNEDDS with a drug load of 80% of Seq (SNEDDS 80%),
supersaturated in SNEDDS at 200% Seq (Super-SNEDDS solution),
and suspended in SNEDDS containing R3040 or CIN at 200% Seq
(Super-SNEDDS suspension), as the Chasing Principle and aqueous
suspension5. The rank order of absorption for CIN dosed in the
dosing regimens was SNEDDS 80%¼Chasing Principle4Super-
SNEDDS solution¼Super-SNEDDS suspension4aqueous suspen-
sion. For R3040, the ranking of drug absorption changed to
SNEDDS 80%¼Super-SNEDDS solution4Super-SNEDDS sus-
pension4Chasing Principle4aqueous suspension. Thus, CIN
dosed in the Chasing Principle produced similar absorptions proﬁles
to CIN dosed dissolved in SNEDDS, while R3040 did not show
signiﬁcant absorption improvement upon dosing in the Chasing
Principle5,26.
The higher capacity of F65, F55 and F20 to solubilize CAR
(Fig. 4) compared to the ability of F65, F55 and F20 to solubilize
CIN (Fig. 5) and R3040 (Fig. 6) may be related to the lower logP of
CAR and consequently higher Seq in the gastric and intestinal
medium as compared to CIN (logP 5.8) and R3040 (logP 10.4)
(Table 3). The high capacity of the drug-free SNEDDS to solubilize
CAR in this work indicates that the in vivo dosing of CAR in the
Chasing Principle could provide improved CAR absorption and/or
similar absorptions proﬁles to CAR dosed dissolved in SNEDDS, as
shown above for CIN. However, a pharmacokinetic study needs to be
performed to conﬁrm this hypothesis.4. Conclusions
The purpose of this study was to evaluate if the composition of
SNEDDS used in the Chasing Principle would affect drug
solubilization and if high drug Seq in SNEDDS would result in a
high drug solubilization during in vitro lipolysis. In addition, the
correlation between logP and the solubilization of the drug during
in vitro lipolysis when dosed in the Chasing Principle was
assessed. The data obtained in this study established that the
composition of the drug-free SNEDDS inﬂuenced the solubiliza-
tion of CIN, but not R3040 and CAR, implying that the effect of
the SNEDDS composition is compound speciﬁc. It is important to
attempt, though, that the levels of solubilization of CAR and CIN
dosed in the Chasing Principle were higher than for R3040.
Furthermore, even the high bile salt concentration (50 mmol/L)
used in the intestinal step of the in vitro lipolysis was not able to
induce drug solubilization at the same level as when adding drug-
free SNEDDS. While there was no correlation between drug Seq in
SNEDDS and drug solubilization during in vitro lipolysis, CAR,
which had the lowest logP, showed a higher solubilization during
in vitro lipolysis, compared to CIN (logP 5.8) and R3040 (logP 10.4),
Scheyla Daniela Siqueira Jørgensen et al.200suggesting that there is a relation between drug logP and drug
solubilization. For a better understanding of the utility of the Chasing
Principle, however, further studies with different drug-free SNEDDS
and model drugs are desirable.Acknowledgments
The authors would like to acknowledge F. Hoffmann-La Roche
Ltd., Basel (1073861001), Switzerland for the ﬁnancial support
and the CAPES Foundation, Ministry of Education of Brazil,
Brasília (009416/2013-07) for the ﬁnancial support of Ph.D
student Scheyla Siqueira.References
1. Kuentz M, Holm R, Elder DP. Methodology of oral formulation
selection in the pharmaceutical industry. Eur J Pharm Sci
2016;87:136–63.
2. Michaelsen MH, Wasan KM, Sivak O, Müllertz A, Rades T. The
effect of digestion and drug load on halofantrine absorption from self-
nanoemulsifying drug delivery system (SNEDDS). AAPS
J 2015;18:180–6.
3. MacGregor KJ, Embleton JK, Lacy JE, Perry EA, Solomon LJ, Seager
H, et al. Inﬂuence of lipolysis on drug absorption from the gastro-
intestinal tract. Adv Drug Deliv Rev 1997;25:33–46.
4. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral
delivery of poorly water soluble drugs. Adv Drug Deliv Rev
1997;25:103–28.
5. Siqueira SD, Müllertz A, Gräeser K, Kasten G, Mu H, Rades T.
Inﬂuence of drug load and physical form of cinnarizine in new
SNEDDS dosing regimens: in vivo and in vitro evaluations. AAPS
J 2017;19:587–94.
6. Larsen AT, Sassene P, Mullertz A. In vitro lipolysis models as a tool
for the characterization of oral lipid and surfactant based drug delivery
systems. Int J Pharm 2011;417:245–55.
7. Mahmoud EA, Bendas ER, Mohamed MI. Preparation and evaluation
of self-nanoemulsifying tablets of carvedilol. AAPS PharmSciTech
2009;10:183–92.
8. Shekhawat PB, Pokharkar VB. Understanding peroral absorption:
regulatory aspects and contemporary approaches to tackling solubility
and permeability hurdles. Acta Pharm Sin B 2017;7:260–80.
9. Thomas N, Richter K, Pedersen TB, Holm R, Müllertz A, Rades T.
In vitro lipolysis data does not adequately predict the in vivo
performance of lipid-based drug delivery systems containing fenoﬁ-
brate. AAPS J 2014;16:539–49.
10. Khan J, Rades T, Boyd B. The precipitation behavior of poorly water-
soluble drugs with an emphasis on the digestion of lipid based
formulations. Pharm Res 2016;33:548–62.
11. Kollipara S, Gandhi RK. Pharmacokinetic aspects and in vitro–in vivo
correlation potential for lipid-based formulations. Acta Pharm Sin B
2014;4:333–49.
12. Christiansen ML, Holm R, Abrahamsson B, Jacobsen J, Kristensen J,
Andersen JR, et al. Effect of food intake and co-administration of
placebo self-nanoemulsifying drug delivery systems on the absorption
of cinnarizine in healthy human volunteers. Eur J Pharm Sci
2016;84:77–82.
13. Carrigan PJ, Bates TR. Biopharmaceutics of drugs administered in
lipid-containing dosage forms I: GI absorption of griseofulvin from an
oil-in-water emulsion in the rat. J Pharm Sci 1973;62:1476–9.
14. Chakrabarti S, Belpaire FM. Bioavailability of phenytoin in lipid
containing dosage forms in rats. J Pharm Pharmacol 1978;30:330–1.
15. Larsen A, Holm R, Pedersen ML, Müllertz A. Lipid-based formula-
tions for danazol containing a digestible surfactant, labraﬁl M2125CS:
in vivo bioavailability and dynamic in vitro lipolysis. Pharm Res
2008;25:2769–77.16. Kleberg K, Jacobsen F, Fatouros DG, Müllertz A. Biorelevant media
simulating fed state intestinal ﬂuids: colloid phase characterization and
impact on solubilization capacity. J Pharm Sci 2010;99:3522–32.
17. Kostewicz ES, Brauns U, Becker R, Dressman JB. Forecasting the
oral absorption behavior of poorly soluble weak bases using
solubility and dissolution studies in biorelevant media. Pharm Res
2002;19:345–9.
18. Hernell O, Staggers JE, Carey MC. Physical-chemical behavior of
dietary and biliary lipids during intestinal digestion and absorption. 2.
Phase analysis and aggregation states of luminal lipids during
duodenal fat digestion in healthy adult human beings. Biochemistry
1990;29:2041–56.
19. Fatouros DG, Walrand I, Bergenstahl B, Müllertz A. Colloidal
structures in media simulating intestinal fed state conditions with
and without lipolysis products. Pharm Res 2009;26:361–74.
20. Persson EM, Gustafsson AS, Carlsson AS, Nilsson RG, Knutson L,
Forsell P, et al. The effects of food on the dissolution of poorly soluble
drugs in human and in model small intestinal ﬂuids. Pharm Res
2005;22:2141–51.
21. Tran T, Siqueira SD, Amenitsch H, Rades T, Müllertz A. Monoacyl
phosphatidylcholine inhibits the formation of lipid multilamellar
structures during in vitro lipolysis of self-emulsifying drug delivery
systems. Eur J Pharm Sci 2017;108:62–70.
22. Larsen AT, Holm R, Müllertz A. Solution or suspension–does it matter
for lipid based systems? In vivo studies of chase dosing lipid vehicles
with aqueous suspensions of a poorly soluble drug. Eur J Pharm
Biopharm 2017;117:308–14.
23. Doughty RN, White HD. Carvedilol: use in chronic heart failure.
Expert Rev Cardiovasc Ther 2007;5:21–31.
24. Thomas N, Müllertz A, Graf A, Rades T. Inﬂuence of lipid composi-
tion and drug load on the in vitro performance of self-nanoemulsifying
drug delivery systems. J Pharm Sci 2012;101:1721–31.
25. Tanaka Y, Hara T, Waki R, Nagata S. Regional differences in the
components of luminal water from rat gastrointestinal tract and
comparison with other species. J Pharm Pharm Sci 2012;15:510–8.
26. Siqueira Jørgensen SD, Al Sawaf M, Graeser K, Mu H, Müllertz
A, Rades T. The ability of two in vitro lipolysis models reﬂecting the
human and rat gastro-intestinal conditions to predict the in vivo
performance of SNEDDS dosing regimens. Eur J Pharm Biopharm
2018;124:116–24.
27. Carrière F, Renou C, Lopez V, De Caro J, Ferrato F, Lengsfeld H,
et al. The speciﬁc activities of human digestive lipases measured from
the in vivo and in vitro lipolysis of test meals. Gastroenterology
2000;119:949–60.
28. Christophersen PC, Christiansen ML, Holm R, Kristensen J, Jacobsen
J, Abrahamsson B, et al. Fed and fasted state gastro-intestinal in vitro
lipolysis: in vitro in vivo relations of a conventional tablet, a SNEDDS
and a solidiﬁed SNEDDS. Eur J Pharm Sci 2014;57:232–9.
29. Thomas N, Holm R, Müllertz A, Rades T. In vitro and in vivo
performance of novel supersaturated self-nanoemulsifying drug deliv-
ery systems (super-SNEDDS). J Control Release 2012;160:25–32.
30. Brittain HG. In: Proﬁles of drug substances, excipients and related
methodology. 1st ed. San Diego, CA: Elsevier Academic Press; 2013.
31. Budavar S, O'Neil MJ, Smith A, Heckelman PE. Cinnarizine. In: The
merck index. 11th ed. Rahway: Merck and Co., Inc.; 1989. p. 359.
32. F. Hoffmann-La Roche. Datasheet of compound CSE-3040, 2014.
33. Larsen AT, Ogbonna A, Abu-Rmaileh R, Abrahamsson B, Østergaard
J, Müllertz A. SNEDDS containing poorly water soluble cinnarizine;
development and in vitro characterization of dispersion, digestion and
solubilization. Pharmaceutics 2012;4:641–65.
34. Larsen AT, Ohlsson AG, Polentarutti B, Barker RA, Phillips AR, Abu-
Rmaileh R, et al. Oral bioavailability of cinnarizine in dogs: relation to
SNEDDS droplet size, drug solubility and in vitro precipitation. Eur
J Pharm Sci 2013;48:339–50.
35. Phan S, Salentinig S, Prestidge CA, Boyd BJ. Self-assembled
structures formed during lipid digestion: characterization and implica-
tions for oral lipid-based drug delivery systems. Drug Deliv Transl Res
2014;4:275–94.
Exploring the utility of the Chasing Principle 20136. Kaukonen AM, Boyd BJ, Porter CJH, Charman WN. Drug solubiliza-
tion behavior during in vitro digestion of simple triglyceride lipid
solution formulations. Pharm Res 2004;21:245–53.
37. Larsen AT, Åkesson P, Juréus A, Saaby L, Abu-Rmaileh R,
Abrahamsson B, et al. Bioavailability of cinnarizine in
dogs: effect of SNEDDS loading level and correlation with
cinnarizine solubilization during in vitro lipolysis. Pharm Res
2013;30:3101–13.38. Sassene PJ, Knopp MM, Hesselkilde JZ, Koradia V, Larsen A, Rades
T, et al. Precipitation of a poorly soluble model drug during in vitro
lipolysis: characterization and dissolution of the precipitate. J Pharm
Sci 2010;99:4982–91.
39. Tran T, Rades T, Müllertz A. Formulation of self-nanoemulsifying
drug delivery systems containing monoacyl phosphatidylcholine and
Kolliphor® RH40 using experimental design. Asian J Pharm Sci
2017;13:536-45.
